our Premium Content: News alerts, weekly reports and conference planners

GENE:

NCOA1 (Nuclear Receptor Coactivator 1)

News alerts, weekly reports and conference planners

Layered Single-Cell Heterogeneity in Hormone Receptor Signaling Across Mouse Organoids and Human ERα+ Cancer Cells. (PubMed, bioRxiv)

Using murine mammary organoids, we mapped estrogen (E2) and progesterone (P4) responses at single-cell resolution...MCF7 cells show delayed activation kinetics and reach a lower response plateau. Together, these findings reveal that hormone response magnitude varies independently of receptor abundance in mammary organoids and follows distinct activation dynamics in human ERα + cancer cells.

6 days ago

Preclinical • Journal

NCOR1 (Nuclear Receptor Corepressor 1) • NCOR2 (Nuclear Receptor Corepressor 2) • NCOA1 (Nuclear Receptor Coactivator 1)

EP300/NCOA1 complex drives glioma angiogenesis via H3K27 acetylation-dependent activation of VEGFA. (PubMed, Exp Cell Res)

Co-immunoprecipitation and nuclear-cytoplasmic assays confirmed that EP300 forms a nuclear transcriptional co-activator complex with NCOA1, which stabilizes its nuclear localization and synergistically enhances VEGFA expression. Together, these findings identify EP300 as a central epigenetic regulator of glioma angiogenesis and highlight the EP300/NCOA1-VEGFA axis as a potential therapeutic target.

7 days ago

Journal

VEGFA (Vascular endothelial growth factor A) • EP300 (E1A binding protein p300) • NCOA1 (Nuclear Receptor Coactivator 1)

2ms

Potential mechanisms of Si-Wu-Tang against esophageal squamous cell carcinoma: A machine learning pharmacological study. (PubMed, Medicine (Baltimore))

Molecular docking demonstrated the presence of affinity between target hub proteins and active compounds. This study revealed that SWT might exert its therapeutic effects on ESCC through multi-targets and multi-mechanisms.

2 months ago

Journal

CDK1 (Cyclin-dependent kinase 1) • CHRM3 (Cholinergic Receptor Muscarinic 3) • NCOA1 (Nuclear Receptor Coactivator 1)

2ms

EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway (clinicaltrials.gov)

P3, N=296, Active, not recruiting, Rhythm Pharmaceuticals, Inc. | Trial completion date: Dec 2025 --> Dec 2026

2 months ago

Trial completion date

NCOA1 (Nuclear Receptor Coactivator 1) • PCSK1 (Proprotein Convertase Subtilisin/Kexin Type 1)

3ms

Leptin Drives Breast Cancer Aggressiveness Acting Through the Activation of the NCOA1/STAT3 Pathway. (PubMed, Med Sci (Basel))

Obesity-associated hyperleptinemia enhances aggressiveness in BC through a mechanism involving LEPR-mediated activation pathways encompassing NCOA1/STAT3, which drive proliferation, migration, and EMT. This assigns a potential therapeutic utility for obesity-related advancements found within BC pathology.

3 months ago

Journal • BRCA Biomarker

CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • LEP (Leptin) • NCOA1 (Nuclear Receptor Coactivator 1)

3ms

Cross-Regional Transcriptome Data Reveal Transcriptional Abnormalities Associated with Lung Adenocarcinoma. (PubMed, Rep Biochem Mol Biol)

Our findings suggest that the expression levels of serglycin, ILK, ESD, and PLPD1 may play a significant role in the development of LAC. This information can be valuable for identifying potential treatment targets for lung cancer.

3 months ago

Journal

CD123 (Interleukin 3 Receptor Subunit Alpha) • SPARC (Secreted Protein Acidic And Cysteine Rich) • VIM (Vimentin) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • KRT19 (Keratin 19) • AQP1 (Aquaporin 1) • BST1 (Bone Marrow Stromal Cell Antigen 1) • COL3A1 (Collagen Type III Alpha 1 Chain) • SMAD7 (SMAD Family Member 7) • TAGLN (Transgelin) • ADH1B (Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide) • AIMP2 (Aminoacyl TRNA Synthetase Complex Interacting Multifunctional Protein 2) • AKAP12 (A-Kinase Anchoring Protein 12) • RGS2 (Regulator Of G Protein Signaling 2) • NCOA1 (Nuclear Receptor Coactivator 1)

4ms

GREB1-rearranged uterine tumour shares a common DNA methylation signature with ESR1-rearranged UTROSCT. (PubMed, Histopathology)

Overall, our findings confirm that GREB1-rearranged uterine tumours are part of the UTROSCT spectrum, though they frequently exhibit a more diffuse growth pattern and a higher degree of genomic instability.

4 months ago

Journal

ER (Estrogen receptor) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • NR4A3 (Nuclear receptor subfamily 4 group A member 3) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex) • NCOA2 (Nuclear Receptor Coactivator 2) • NCOA1 (Nuclear Receptor Coactivator 1)

4ms

Decoding UTROSCT heterogeneity: systematic clinicopathological evaluation combined with molecular profiling. (PubMed, J Pathol Clin Res)

These genetic alterations were conspicuously absent in primary tumors, suggesting their potential role in metastatic progression. Our findings represent the first demonstration of CNV-driven oncogenic evolution in UTROSCTs, particularly implicating SWI/SNF complex dysregulation in metastatic competence.

4 months ago

Journal

ER (Estrogen receptor) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • ATRX (ATRX Chromatin Remodeler) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex) • NCOA2 (Nuclear Receptor Coactivator 2) • NCOA3 (Nuclear Receptor Coactivator 3) • NCOA1 (Nuclear Receptor Coactivator 1)

5ms

ZFTA::NCOA1/2-rearranged Epithelioid Mesenchymal Tumor-A Phenotypically Distinct Myoepithelial-like Neoplasm Epigenetically Overlapping with Chondroid Lipoma. (PubMed, Mod Pathol)

In conclusion, ZFTA::NCOA1/2-rearranged epithelioid mesenchymal tumors represent a novel, morphologically distinct entity, genetically and epigenetically overlapping with chondroid lipoma. Expanded cohorts and long-term follow-up are necessary to clarify their precise classification and biologic behavior.

5 months ago

Journal

NCOA2 (Nuclear Receptor Coactivator 2) • RELA (RELA Proto-Oncogene) • ZFTA (Zinc Finger Translocation Associated) • NCOA1 (Nuclear Receptor Coactivator 1)

5ms

In Silico Characterization of Pathogenic ESR2 Coding and UTR Variants as Oncogenic Potential Biomarkers in Hormone-Dependent Cancers. (PubMed, Genes (Basel))

This integrative analysis prioritizes high-impact ESR2 variants that likely impair ERβ1 structure and shows context-dependent clinical effects. Despite their generally low frequency (except for rs4986938), prospective validation linking variant class to ERβ expression and survival outcomes is needed to support biomarker development and therapeutic applications.

5 months ago

Journal • BRCA Biomarker

ER (Estrogen receptor) • BRCA (Breast cancer early onset) • NCOA1 (Nuclear Receptor Coactivator 1)

6ms

Transcriptomic Profile of the Trastuzumab-Resistant Breast Cancer Cell Line BT-474 (PubMed, Mol Biol (Mosk))

The changes identified indicate a complex reprogramming of transcriptional activity affecting cell cycle processes, DNA repair, metabolism, and the epithelial-mesenchymal transition. The findings expand our understanding of the molecular mechanisms of trastuzumab resistance and open prospects for the development of novel therapeutic strategies to overcome drug resistance in HER2-positive breast cancer.

6 months ago

Preclinical • Journal

HER-2 (Human epidermal growth factor receptor 2) • POLD1 (DNA Polymerase Delta 1) • POLD2 (DNA Polymerase Delta 2) • YBX1 (Y-Box Binding Protein 1) • E2F1 (E2F transcription factor 1) • FSTL1 (Follistatin Like 1) • HEY1 (Hes Related Family BHLH Transcription Factor With YRPW Motif 1) • NFIC (Nuclear Factor I C) • TFAP2A (Transcription Factor AP-2 Alpha) • NCOA1 (Nuclear Receptor Coactivator 1)

HER-2 positive

Herceptin (trastuzumab)

6ms

Clinicopathologic and Molecular Genetic Features of Spindle Cell Rhabdomyosarcoma harboring ZFP64::NCOA2/3 fusions: A Series of 14 Cases. (PubMed, Mod Pathol)

We conclude that SCRMS with ZFP64::NCOA2/3 fusions represent a distinct, clinically aggressive sarcoma, characterized by fascicular and sometimes round cell morphology, occasional chondro-osseous differentiation and variable skeletal muscle marker expression. Recognition of this emerging subtype of SCRMS may have prognostic and therapeutic implications.

6 months ago

Journal

ALK (Anaplastic lymphoma kinase) • MEIS1 (Meis Homeobox 1) • TFCP2 (Transcription Factor CP2) • MYOD1 (Myogenic Differentiation 1) • NCOA2 (Nuclear Receptor Coactivator 2) • NCOA3 (Nuclear Receptor Coactivator 3) • VGLL3 (Vestigial Like Family Member 3) • NCOA1 (Nuclear Receptor Coactivator 1)